Order Entry
United States
ContactUsLinkComponent
Ecotest COVID-19 IgG/IgM Rapid Test Device, BTNX
Ecotest COVID-19 IgG/IgM Rapid Test Device, BTNX
  76473-400
 :  Avantor
 :  
undefined
Ecotest COVID-19 IgG/IgM Rapid Test Device, BTNX
  76473-400
 :  Avantor
 :  

 

  • Description:
    Ecotest COVID-19 IgG/IgM rapid test device
  • Cat. No.:
    76473-400
  • Storage temperature:
    2...30 °C (35.6...86 °F)

 

 

The Ecotest COVID-19 IgG/IgM Rapid Test Device is a rapid lateral flow chromatographic immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, plasma (sodium EDTA) and fingerstick whole blood. The Ecotest COVID-19 IgG/IgM Rapid Test Device is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Ecotest COVID-19 IgG/IgM Rapid Test Device should not be used to diagnose acute SARS-CoV-2 infection.

  • Lateral flow chromatographic immunoassay
  • Rapid results in 15 minutes
  • Detects IgM and IgG antibodies specific to SARS-CoV-2
  • Cassettes are sealed in individual pouches
  • Results are interpreted through color development on the strip
  • Run time: 15 minutes

This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests. This test is also authorized for use with fingerstick whole blood specimens only at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E. Results from antibody testing should not be used to diagnose or exclude SARS-CoV-2 infection or to inform infection status. Not for the screening of donated blood.

Please see the related information tab below for the patient fact sheet, health care professional fact sheet, instructions for use and FDA EUA letter.

 : Use of this test with all authorized specimen types is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests. This test is also authorized for use with fingerstick whole blood specimens only at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
 : Includes, 20 individually packed test devices, 20 disposable pipettes, 20 sterile safety lancet, buffer, package insert and alcohol prep pad. External negative and positive control (Available upon request).
 : For Emergency Use Authorization only. For prescription use only. For in vitro diagnostic use only.